Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use

AIDS

Volumn 19, Issue 11, 2005, Pages 1189-1195

  Wood, Evan ^a,b   Hogg, Robert S ^a,b   Yip, Benita ^a   Dong, Winnie W Y ^a   Wynhoven, Brian ^a   Mo, Theresa ^a   Brumme, Chanson J ^a   Montaner, Julio S G ^a,b   Harrigan, P Richard ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AIDS; Antiretrovirals; HIV; Injection drug use; Resistance

Indexed keywords

LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 23044451460     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000176219.48484.f1     Document Type: Article

References (32)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
2. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-F43.
3. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 Cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577.
4. Wood E, Montaner JS, Yip B, Tyndall MW, Schlechter MT, O'Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003; 169:656-661.
5. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis 2000; 30 (Suppl 2):S177-S184.
6. Dybul M, Fauci AS, Bartlett JC, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137:381-433.
7. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-235.
8. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362:2002-2011.
9. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-1983.
10. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA 1997; 278:63-65.
11. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
12. Alexander CS, Dong W, Schechter MT, O'Shaughnessy MV, Strathdee SA, Mo T, et al. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. AIDS 1999; 13:981-985.
13. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999; 21:114-119.
14. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Commun Health 1999; 53:4-8.
15. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:435-442.
16. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: two potential futures. AIDS 2000; 14:1229-1235.
17. The Determinants of the HIV/AIDS Epidemics in Eastern Europe. Online: http://www.mapnetwork.org/docs/Map_ EastEurope_1998_Revised290304.pdf.
18. Wood E, Montaner JS, Bangsberg D, Tydall MW, Strathdee S, O'Shaughnessy MV, et al. Extending access to HIV antiretrviral therapy to marginalized populations in the developed world. AIDS 2003; 17:2419-2427.
19. Kitayaporn D, Uneklabh C, Weniger BG, Lohsomboon P, Kaewkungwal J, Morgan WM, et al. HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. AIDS 1994; 8:1443-1450.
20. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/ AIDS antiretroviral treatment. J Acquir Immune Defic Syndr 2000; 23:396-404.
21. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L Ann Intern Med 2003; 139:810-816.
22. Wood E, Montaner JS, Schechter MT, Tyndall MW, O'Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated HIV-1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis 2003; 188:1164-1170.
23. Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002; 16:2065-2072.
24. Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WW, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004; 190:285-292.
25. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:92-96.
26. Wood E, Montaner JS, Braitstein P, Yip B, Schechter MT, O'Shaughnessy MV, et al. Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health. Int J Drug Pol 2003; 15:133-138.
27. Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA 1998; 280:567-568.
28. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:47-58.
29. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, Guzman D, et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis 2004; 190:162-165. Epub 2004 Jun 2009.
30. Kerr T, Wodak A, Elliot R, Montaner JS, Wood E. Opioid substitution and HIV/AIDS treatment and prevention. Lancet 2004; 364:1918-1819.
31. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280:547-549.
32. Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, et al. Staging for antiretroviral therapy among HIV-infected drug users. JAMA 2004; 292:1175-1177.